EP Patent

EP3325488A1 — Chiral diaryl macrocycles and uses thereof

Assigned to Turning Point Therapeutics Inc · Expires 2018-05-30 · 8y expired

What this patent protects

This disclosure relates to the use of certain diaryl macrocycle compounds, specifically (7 S 13 R )-11-fluoro-7,13-dimethyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3- f ][1,4,8,10]benzoxatriazacyclotridecin-4(5 H )-one in the treatment of disease in mammals. This disclosure al…

USPTO Abstract

This disclosure relates to the use of certain diaryl macrocycle compounds, specifically (7 S 13 R )-11-fluoro-7,13-dimethyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3- f ][1,4,8,10]benzoxatriazacyclotridecin-4(5 H )-one in the treatment of disease in mammals. This disclosure also relates to compositions including such compounds, and to methods of using such compositions in the treatment of diseases in mammals, especially in humans.

Drugs covered by this patent

Patent Metadata

Patent number
EP3325488A1
Jurisdiction
EP
Classification
—
Expires
2018-05-30
Drug substance claim
No
Drug product claim
No
Assignee
Turning Point Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.